Delpacibart etedesiran

RNA / oligonucleotide

Also known as EWF980, AOC 1001

Phase 3topline reported

Evidence outlook · registrational

Myotonic Dystrophy Type 1: topline reported 2026-09-08

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-09-08 (Phase III HARBOR misses primary endpoint of vHOT). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Myotonic Dystrophy Type 1
NCT07008469 · Avidity Biosciences, Inc.
2025-06-26 – 2030-10 · Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
What this study did
NCT06411288 · Avidity Biosciences, Inc.
2024-05-30 – 2026-07-29 · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
What this study did
Phase 2 (1)
Myotonic Dystrophy Type 1
NCT05479981 · Avidity Biosciences, Inc.
2022-08-04 – 2025-09-10 · DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
What this study did
Phase 1/2 (1)
Myotonic Dystrophy Type 1
NCT05027269 · Avidity Biosciences, Inc.
2021-10-28 – 2023-02-14 · DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Myotonic Dystrophy Type 1: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Delpacibart Etedesiran: this drugPhase 3RNA / oligonucleotideDMPKnot yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
VX-670Phase 2RNA / oligonucleotideDMPK CUG-repeat RNAnot yet gradedNo reviewed efficacy summary in this indication
SAR446268Phase 1/2Gene therapy / editingDMPKnot yet gradedNo reviewed efficacy summary in this indication
SRP-1003
Phase 1/2(overall)
RNA / oligonucleotideDMPK (dystrophia myotonica protein kinase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Delpacibart etedesiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
October 2030 (1)
Phase 3Myotonic Dystrophy Type 1Enrolling by invitation
Est. primary completion 2030-10 · NCT07008469 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultPhase III HARBOR misses primary endpoint of vHOT